Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2003
10/22/2003EP1104446B1 Biologically active fraction of vegetable melanin, process for its production and its use
10/22/2003EP1056744B1 6,9-disubstituted 2- trans-(4- aminocyclohexyl) amino]purines
10/22/2003EP1047665B1 Matrix metalloprotease inhibitors
10/22/2003EP0934746B1 Substance in the form of an aqueous extract of vegetal raw material for treating oncological diseases, and method for producing the same
10/22/2003EP0929293B1 Liposomes containing a cisplatin compound
10/22/2003EP0815221B1 A novel growth factor and a genetic sequence encoding same
10/22/2003EP0764167B1 Bicycling lactam inhibitor of interleukin-1-beta converting enzyme
10/22/2003EP0658209B1 Endothelial lineage specific transcriptional regulatory element from tek
10/22/2003CN1451045A IFN-alpha homologues
10/22/2003CN1451016A Human cervical cancer suppressor protein, polynucleotide encoding the protein cell transformed with the polynucleotide and method
10/22/2003CN1451006A I-[alkyl] 1-[(heteroaryl) alkyl] and 1 [(aryl) alkyl] 7-pyridinyl-imidazo [1,2-a] pyrimidin-5(1h)-one derivatives
10/22/2003CN1451004A 7-oxo pyridopyrimidines
10/22/2003CN1450999A Novel piperazine derivatives
10/22/2003CN1450991A Hydroxamate derives useful as deacetylase inhibitors
10/22/2003CN1450923A Method and compositions for administering taxanes orally to human patients
10/22/2003CN1450914A Preparation of aqueous clear solution dosage forms with bile acids
10/22/2003CN1450913A Combination use of bisphosphonates, estrogenic agents and optionally estrogens
10/22/2003CN1450911A New clinical parameters for determining hematologic toxicity proior to radioimmunotherapy
10/22/2003CN1450910A Mutant simplex virus for treating hyperproliferative cell growth
10/22/2003CN1450907A Beta glycan as an inhibin receptor and uses thereof
10/22/2003CN1450905A Method for improving the cell protection
10/22/2003CN1450900A Antitumor agents
10/22/2003CN1450891A Formulation based on heparin, glycosaminogl ycan or heparinoid, use of the formulation and the formulation base
10/22/2003CN1449834A Use of 2-hydroxypropyl beta-cyclodextrin in preparing sodium new houttuy fonate injection
10/22/2003CN1449812A Compound Chinese medicine for treating extensive cancer
10/22/2003CN1449799A Traditional Chinese medicine injection for treating tumor and preparation process thereof
10/22/2003CN1449793A Anti-cancer medicine and preparation process thereof
10/22/2003CN1449787A Medicine for treating various kinds of cancer
10/22/2003CN1449771A Repellent mixture for department of gynecology
10/22/2003CN1125183C Preparation process of Lidamycin as one antineoplastic antibiotics
10/22/2003CN1125083C Monoclonal antibody active against CD44V6
10/22/2003CN1125082C Human chemokine beta-8 chemokine beta-1 and macrophage inflammatory protein-4
10/22/2003CN1125079C Cyclopeptolides
10/22/2003CN1125070C Pyrrolo [2,3-d] pyrmidine compounds, and compositions and use thereof
10/22/2003CN1125061C C2 taxane derivatives and pharmaceutical compositions containing them
10/22/2003CN1125060C C-10 taxane derivatives and pharmaceutical compositions containing them
10/22/2003CN1125054C Novel imidazolidine derivatives, their preparation their use and pharmaceutical preparations comprising them
10/22/2003CN1125049C New crystal modification N of torasemide
10/22/2003CN1124858C Medicine for treating blood vessel embolism and its preparing process
10/22/2003CN1124854C Chinese medicine for curing gastnopathy
10/22/2003CN1124848C Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
10/22/2003CN1124846C (N.N')-bis (sulfonyl) hydrazines useful as antineoplastic agents
10/22/2003CA2424577A1 Use of huntingtin and related compounds for modulating cell survival
10/21/2003US6635776 Lipoxin compounds and their use in treating cell proliferative disorders
10/21/2003US6635762 Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use
10/21/2003US6635749 Auxotrophic attenuated strain of Listeria with a mutation in genes whose protein product is essential for growth used to elicit a t-cell immune response to an antigen
10/21/2003US6635748 Protein for use as antitumor agent; for use as antimetastsis agent
10/21/2003US6635744 Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders
10/21/2003US6635677 Potentiating toxicity of 1,3-bis(chloroethyl)2-nitrosourea
10/21/2003US6635671 Compounds which affect mRNA stability and uses therefor
10/21/2003US6635669 Kinase inhibitor; benign prostatic hyperplasia
10/21/2003US6635666 Cancer treatment with epothilones
10/21/2003US6635656 Cytotoxic alkaloids halitulin
10/21/2003US6635650 Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders
10/21/2003US6635649 Piperazinedione compounds
10/21/2003US6635644 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635641 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/21/2003US6635640 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
10/21/2003US6635629 For therapy and prophylaxis of inflammation, asthma, an allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, solid tumors, AIDS, ischemia, and cardiac arrhythmias
10/21/2003US6635627 Anti-cancer products for treating cystic fibrosis
10/21/2003US6635622 Having anti-tumor activity and immunostimulating activity
10/21/2003US6635621 Alpha amino acid amide derivatives; reducing cathepsins B, L, S and/or K activity
10/21/2003US6635483 Antisense polynucleotide targeted to a nucleic acid encoding the gene, thereby suppressing its expression; cDNA encapsulated in liposome; use as antitumor, anticarcinogenic or antiapoptotic; Alzheimer's disease
10/21/2003US6635462 Mutated form of arginine deiminase
10/21/2003US6635461 Encoded by isolated nucleic acid; has glycosyltransferase activity; given amino acid sequence; useful as diagnostic and therapeutic agent for cancer and thymus-related disorders
10/21/2003US6635451 Conversion of dihomo-gamma linolenic acid (DGLA) to arachidonic acid and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA); Delta 6 desaturase and Delta 5 desaturase
10/21/2003US6635431 Recombinant lipolysis stimulated (LSR) comprising polypeptide of given sequence; use for selecting a compound for enhancing lipoprotein uptake in cells expressing the polypeptide
10/21/2003US6635287 Obtaining an extract from producer cells derived from an organism which is xenogeneic to said target cells and which is capable of entering into a dormant state
10/21/2003US6635255 CASB414:antigen overexpressed in several tumors
10/21/2003US6635244 Adenovirus E1B-55K single amino acid mutants and methods of use
10/21/2003US6635234 Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
10/21/2003CA2257898C Use of aminothiolester derivatives in pharmaceutics
10/21/2003CA2237401C Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides
10/21/2003CA2213737C 2-arylbenzazole compounds
10/21/2003CA2182289C Immuno-stimulatory monoclonal antibodies
10/21/2003CA2115049C Dna sequences encoding gelonin polypeptide
10/21/2003CA2093896C Hormone labelling with rhenium and technetium
10/21/2003CA2076432C Humanized antibody derivatives that recognize difucosyl lewis blood group antigens y-6 and b-7-2
10/21/2003CA2017166C Metalloproteinase inhibitor
10/16/2003WO2003085377A2 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003WO2003085134A2 Methods of diagnosing and treating colorectal cancer
10/16/2003WO2003085125A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/16/2003WO2003085119A1 METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
10/16/2003WO2003085118A1 Process for producing antibody composition
10/16/2003WO2003085110A2 Oligomeric compounds for the modulation hif-1alpha expression
10/16/2003WO2003085107A1 Cells with modified genome
10/16/2003WO2003085106A1 Preventives and/or remedies for cancer
10/16/2003WO2003085102A1 Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
10/16/2003WO2003085090A2 A human ribonucleotide reductase m2 subunit
10/16/2003WO2003085087A2 Modified cea nucleic acid and expression vectors
10/16/2003WO2003084999A1 Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
10/16/2003WO2003084996A2 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/16/2003WO2003084984A1 Heterocyclic amides with alpha-4 integrin antagonist activity
10/16/2003WO2003084963A1 Non-steroidal progesterone receptor modulators
10/16/2003WO2003084956A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
10/16/2003WO2003084954A1 Tropane derivatives as ccr5 modulators
10/16/2003WO2003084951A1 (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
10/16/2003WO2003084948A1 Nitrogenous heterocyclic compound and medicine thereof
10/16/2003WO2003084943A2 Terphenyl derivatives, preparation thereof, compositions containing same
1 ... 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 ... 2211